Restoring Sound, Removing Stigma: Auralytics MedTech’s Vision for Invisible Hearing Implants

In the world of medical technology, some problems remain unsolved not because science is missing but because existing solutions are incomplete. For millions of people with severe hearing loss, cochlear implants have existed for more than two decades, yet the technology has reached only a small fraction of those who need it.

Ragdeep, founder of Auralytics MedTech Private Limited, is working to close that gap by redesigning the cochlear implant itself. Instead of improving existing software or tweaking signal processing layers, the company is attempting something far more fundamental: building a hearing restoration system that can be implanted completely inside the human body.

---

The Hidden Gap in Cochlear Implant Adoption

Globally, cochlear implants are considered one of the most successful medical devices for restoring hearing in patients with severe sensorineural hearing loss. Despite this success, adoption remains surprisingly low.

An estimated 4 to 5 crore people worldwide could benefit from cochlear implants, while conservative estimates suggest more than 1.5 crore potential patients. Yet after more than two decades of availability, only 10 to 20 lakh implantations have been performed globally.

The challenge is not only financial accessibility. It is also a design limitation. Most existing cochlear implant systems require an external processor attached behind the patient’s ear. A microphone captures sound externally and transmits signals to an internal implant that stimulates auditory neurons.

For many patients, particularly children, this external component becomes a social barrier. Parents often hesitate when they learn that their child will need to wear a visible external device throughout life. For Ragdeep, this stigma raised a deeper technical question: what if the entire cochlear implant system could exist inside the body?

---

Building a Fully Implantable Cochlear Implant System

This question led to the development of Intrasonus, the flagship technology currently being built by Auralytics MedTech. The goal is to create a fully implantable cochlear implant system with no external hardware.

At the heart of the system lies a biomimetic acoustic sensor designed to replicate how the human ear naturally processes sound. Traditional cochlear implants capture the entire sound spectrum and then digitally separate frequencies through signal processing. Auralytics is approaching the problem differently by introducing a mechanical frequency discrimination architecture.

The sensor incorporates a cantilever beam array, where each beam is tuned to respond to a specific frequency band. When sound waves enter the system, each cantilever reacts only to its designated frequency range. This allows sound frequencies to be separated mechanically before neural stimulation is delivered with high precision.

The design closely mirrors the natural tonotopic organization of the human cochlea, where different regions of the inner ear respond to different sound frequencies. In effect, the sensing mechanism itself performs the filtering process, reducing the need for heavy digital signal processing and lowering energy consumption. The platform could also support additional hearing technologies in the future, including middle ear implants and advanced hearing aids.

---

When Research Labs Think Like Product Builders

Ragdeep’s journey into hearing restoration technology began inside a research laboratory at Indian Institute of Technology Guwahati. After graduating with an engineering degree, he joined the lab expecting a traditional academic environment centered around research publications.

Instead, he encountered a very different philosophy. The lab treated research not as a paper to be published but as a product to be built. Ideas were expected to evolve into working prototypes, and if a concept could not be converted into a proof of concept, it was rarely pursued further.

This product-oriented mindset shaped the early development of Auralytics MedTech. By the time the company was formally incorporated, the team had already built a working prototype and begun assembling a patent portfolio around its technology. Today the startup holds one granted patent and two patents pending, with additional global filings under preparation.

---

A Surgeon’s Perspective Joins the Startup

The company’s founding team combines engineering research with clinical insight. After Auralytics’ early patent announcement gained attention online, Ragdeep was contacted by Vikram, an engineer with strong connections within the ENT medical ecosystem.

Vikram’s father, Dr. P. G. Vishwanathan, is among the early surgeons who introduced cochlear implant surgeries in India through Vikram ENT Hospital. For Vikram, the technology represented a rare opportunity to work on a next generation cochlear implant platform emerging from an Indian research laboratory.

He joined the company as a co-founder, bringing both industry connections and a clinical perspective that helped accelerate the transition from research project to medical device startup.

---

The Long Road of Deep Tech Medical Devices

Medical device startups operate on timelines very different from those of software companies. Auralytics has been researching hearing technologies since 2017, with the cochlear implant concept taking shape around 2018 and 2019.

The current development stage focuses on integrating three independently tested subsystems into a complete prototype. Once integrated validation is achieved, the technology must move through several additional phases including animal trials, cadaveric testing, clinical protocol development, and regulatory approvals.

The company is targeting first human trials between 2028 and 2029, depending on regulatory approvals and successful testing outcomes. For Class C and Class D medical devices, which represent the highest risk categories, many technologies fail during late-stage clinical validation. This reality makes investment in deep medical technologies particularly challenging, as such ventures require long development cycles and a high tolerance for risk.

---

Manufacturing at the Edge of Precision Engineering

The engineering complexity extends beyond device design. Auralytics’ biomimetic sensor relies on MEMS-based microfabrication, which requires specialized clean room facilities capable of nanometer-scale manufacturing.

Such facilities are typically used in aerospace electronics and semiconductor fabrication. For an early stage medtech startup, gaining access to this level of manufacturing infrastructure is one of the most difficult operational hurdles.

Currently the company works with research-scale fabrication partners, but scaling toward clinical production will eventually require certified medical manufacturing facilities.

---

Market Opportunity for Cochlear Implant Technology

The demand for cochlear implants remains significant. In India alone, approximately one to two children per thousand births experience severe hearing loss. Without timely intervention, many of these children lose both hearing and speech development.

Most cochlear implant procedures in India are funded through government healthcare programs, which means early adoption could be driven by public health initiatives rather than private hospital markets.

Globally, the cochlear implant industry is dominated by three companies: Cochlear Limited, MED-EL, and Advanced Bionics. Together they control nearly 95 percent of the global cochlear implant market.

Auralytics MedTech does not necessarily need to compete directly with these established players. The company remains open to strategic partnerships or technology licensing agreements that could help bring its innovation to patients more quickly. However, one principle remains central to the founders: the technology must remain accessible for low-income countries.

---

Funding and the Next Phase

The startup is currently bootstrapped by its founders and supported through early grants including NEC Ignite. It is also incubated at Bionest IIT Guwahati.

With an estimated runway of six to twelve months, Auralytics is raising ₹4 to ₹5 crore to fund the next phase of development. The capital will support prototype integration, sensor fabrication, team expansion, and preparation for animal trials.

Investor discussions are currently focused on high net worth individuals familiar with medical technology, while institutional investors are waiting for further validation milestones.

---

The Human Reason Behind the Technology

For Ragdeep, the emotional significance of hearing restoration became clearer during his research journey. One quote left a lasting impression, spoken by Helen Keller.

“Blindness cuts us off from things. Deafness cuts us off from people.”

Hearing loss is not simply a sensory impairment. It is a barrier to communication, education, and social participation. Children who cannot hear often struggle to develop speech, leaving them disconnected from the world around them.

Solving hearing restoration therefore becomes more than a technical challenge. It becomes an effort to reconnect people to society itself.

---

North Star

Build hearing implants that disappear.
Let engineering restore connection.

And prove that deep medical technologies emerging from Indian research labs can reach global markets.

Because when a device removes both disability and stigma, it does more than restore hearing.

It restores belonging.